A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
for Colorectal Neoplasms
68 locations incl. Chandler
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024